Immunotherapy has attracted significant interest because of its tremendous potential in cancer therapy. The recent advances in the identification of cancer-associated neoantigens, chimeric antigen receptor (CAR) T-cell and immune checkpoint blockade (ICB), have revolutionized the field of cancer immunotherapy. Cancer immunotherapeutic agents typically exhibit strong immune activation or inhibition activity, thereby inducing robust biological effect even when administered at a small dosage. However, in most cases, cancer immunotherapeutic targets are not cancer specific. Some of them are also expressed in nonmalignant normal tissues and the undesired release of the cancer immunotherapeutic agents into these normal tissues may lead to severe side effects. Thus, the on-demand release of the cancer immunotherapeutic agents into the target site is critical to achieving efficient antitumor immune responses while minimizing the side effects.

中文翻译：

---

癌症免疫疗法的刺激反应平台的最新进展。

免疫治疗由于其在癌症治疗中的巨大潜力而​​引起了极大的兴趣。癌症相关新抗原，嵌合抗原受体（CAR）T细胞和免疫检查点封锁（ICB）鉴定的最新进展，彻底改变了癌症免疫治疗领域。癌症免疫治疗剂通常表现出强大的免疫激活或抑制活性，从而即使以小剂量给药也能诱导强大的生物学作用。但是，在大多数情况下，癌症免疫治疗靶标不是癌症特异性的。它们中的一些也在非恶性正常组织中表达，并且癌症免疫治疗剂不希望地释放到这些正常组织中可能导致严重的副作用。从而，